Provectus Biopharmaceuticals (PVCT) News Today → The #1 Biotech Stock to Have on Your Radar in 2024… (From Huge Alerts) (Ad) Free PVCT Stock Alerts $0.19 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineProvectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancersfinance.yahoo.com - April 18 at 9:10 AMProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creationfinance.yahoo.com - April 16 at 9:34 AMProvectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodiumfinance.yahoo.com - March 27 at 1:37 PMProvectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccinesglobenewswire.com - March 12 at 8:00 AMProvectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meetingglobenewswire.com - March 7 at 8:00 AMProvectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meetingglobenewswire.com - February 29 at 8:00 AMProvectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - February 23 at 1:52 PMProvectus Biopharmaceuticals Announces First Quarter 2024 Conference Callfinance.yahoo.com - February 15 at 10:15 AMProvectus Biopharmaceuticals Announces First Quarter 2024 Conference Callglobenewswire.com - February 15 at 8:00 AMProvectus Biopharmaceuticals Engages irlabs for Investor Relations Servicesfinance.yahoo.com - February 14 at 8:53 AMProvectus Biopharmaceuticals Engages irlabs for Investor Relations Servicesglobenewswire.com - February 14 at 8:00 AMProvectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvantfinance.yahoo.com - December 18 at 8:18 AMProvectus Biopharmaceuticals Inc PVCTmorningstar.com - November 19 at 10:00 AMProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanomafinanznachrichten.de - November 15 at 3:43 PMProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanomafinance.yahoo.com - November 15 at 10:43 AMProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanomafinanznachrichten.de - November 13 at 4:23 PMProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanomafinance.yahoo.com - November 13 at 8:38 AMProvectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meetingfinance.yahoo.com - November 6 at 8:28 AMProvectus Algae Enters Into Livestock Methane Reduction Space Commissioning First Demonstration Biomanufacturing Plantbenzinga.com - November 2 at 1:41 PMProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meetingfinance.yahoo.com - August 7 at 10:20 AMProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congressfinance.yahoo.com - August 1 at 2:36 PMProvectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomasfinance.yahoo.com - June 28 at 9:37 AMPVCT - Provectus Biopharmaceuticals, Inc.finance.yahoo.com - June 3 at 9:52 AMProvectus: Q1 Earnings Snapshotchron.com - May 12 at 9:11 PMProvectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative Bacteriafinance.yahoo.com - April 20 at 10:45 AMHucu.ai and Provectus expand their relationship into a multi-year partnershiptechnews.tmcnet.com - April 18 at 5:23 PMLyophilization Services for Biopharmaceuticals Market Growing Demand and Trends 2023 to 2031marketwatch.com - March 29 at 11:42 PMBiopharmaceutical Third Party Logistics (3PL) Market Growth and Competitive Landscape 2023-2029marketwatch.com - March 27 at 3:45 PMFormer Estée Lauder Executive Joins Provectus Algae as Cosmetics Advisor Signalling Industry Expansionventurebeat.com - March 21 at 2:36 PMFive Areas Where AI Is Revolutionizing The Biopharmaceutical Industryforbes.com - March 17 at 8:13 AMProvectus Algae Receives Strategic Investment from Biotech Leader CJ Bioventurebeat.com - March 1 at 2:31 PMRelative Strength Alert For Day One Biopharmaceuticalsnasdaq.com - February 26 at 8:28 PMBiopharmaceutical Third Party Logistics (3PL) Market Size 2023 Will Touch A New Level In The Upcoming Year 2026marketwatch.com - February 19 at 3:54 PMShort Volatility Alert: Provectus Biopharmbenzinga.com - January 24 at 12:27 PMProvectus Biopharmaceuticals Releases 2023 Stockholder Letterfinance.yahoo.com - January 9 at 8:38 AMNYSE Places Provectus Listing Status Under Reviewthestreet.com - December 31 at 11:10 PMProvectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023finance.yahoo.com - December 12 at 10:26 AMProvectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022finance.yahoo.com - December 1 at 7:13 PMProvectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022finance.yahoo.com - November 10 at 6:32 PMProvectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredientfinance.yahoo.com - November 2 at 7:13 PMProvectus Algae Strengthens R&D Team, Reinforcing Commitment to Delivering Sustainable Synbio Solutionsnz.finance.yahoo.com - October 26 at 1:47 PMProvectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammationfinance.yahoo.com - October 25 at 7:43 AMProvectus Biopharmaceuticals, Inc. (PVCT)finance.yahoo.com - October 20 at 5:42 PMProvectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healingfinance.yahoo.com - September 29 at 11:23 AMProvectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infectionsfinance.yahoo.com - September 21 at 8:32 AMProvectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agentfinance.yahoo.com - August 24 at 1:13 PMProvectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemiafinance.yahoo.com - August 17 at 11:26 AMProvectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repairfinance.yahoo.com - July 19 at 10:47 AMProvectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congressfinance.yahoo.com - June 30 at 6:39 PMProvectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratiofinance.yahoo.com - June 23 at 4:18 PM Get Provectus Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Biotech Stock to Have on Your Radar in 2024… (Ad)Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore! Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now! PVCT Media Mentions By Week PVCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PVCT News Sentiment▼-1.640.43▲Average Medical News Sentiment PVCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PVCT Articles This Week▼10▲PVCT Articles Average Week Get Provectus Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CARM News RLYB News CRVS News IMMX News CELU News CUE News LABP News MNOV News TPST News MRNS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PVCT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
